Show
Sort by
-
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial
-
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial
-
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers
-
The prognostic value of semi-quantitative 123I MIBG scintigraphy at diagnosis in high risk neuroblastoma: validation of the SIOPEN score method
-
EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells
-
Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study
-
Prognostic impact of gene expression-based classification for neuroblastoma
-
Downregulation of miR-449a is essential for the survival of EVI1 positive leukemic cells through modulation of NOTCH1 and BCL2